This is a Validated Antibody Database (VAD) review about mouse Erbb3, based on 53 published articles (read how Labome selects the articles), using Erbb3 antibody in all methods. It is aimed to help Labome visitors find the most suited Erbb3 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Erbb3 synonym: C76256; Erbb-3; Erbb3r; Her3

Invitrogen
mouse monoclonal (2F12)
  • western blot; rat; 1:1000; loading ...; fig 5c
In order to explore the role of Necl4 in peripheral myelination, Invitrogen Erbb3 antibody (NeoMarkers, MS-201-P1) was used in western blot on rat samples at 1:1000 (fig 5c). J Biol Chem (2017) ncbi
mouse monoclonal (2F12)
  • reverse phase protein lysate microarray; human; loading ...; fig 3a
In order to describe the features of 228 primary cervical cancers, Invitrogen Erbb3 antibody (Lab Vision, MS-201-P1ABX) was used in reverse phase protein lysate microarray on human samples (fig 3a). Nature (2017) ncbi
mouse monoclonal (H3.105.5 (Ab105))
  • immunohistochemistry; human; 1:50; loading ...; fig 1
In order to study the role of nuclear ErbB3 in normal and tumor prostate tissues, Invitrogen Erbb3 antibody (Neomarkers, H3.105.5) was used in immunohistochemistry on human samples at 1:50 (fig 1). PLoS ONE (2016) ncbi
mouse monoclonal (2B5)
  • immunoprecipitation; human; loading ...; fig 6
  • immunocytochemistry; human; loading ...; fig 2b
  • western blot; human; loading ...; fig 6
In order to identify adaptors needed for constitutive internalization of ErbB3, Invitrogen Erbb3 antibody (Thermo Fisher, 2B5) was used in immunoprecipitation on human samples (fig 6), in immunocytochemistry on human samples (fig 2b) and in western blot on human samples (fig 6). Biochim Biophys Acta (2016) ncbi
mouse monoclonal (2F12)
In order to identify the effects of the epidermal growth factor receptor 2 and the protein tyrosine kinase 6 in relation to breast cancer treatment, Invitrogen Erbb3 antibody (Thermo Fisher Scientific, MS-201-P1) was used . Mol Oncol (2015) ncbi
mouse monoclonal (2F12)
  • immunoprecipitation; human
  • western blot; human
In order to study mechanism of resistance to the FGFR inhibitor BGJ398 and the FGFR inhibitor ponatinib, Invitrogen Erbb3 antibody (Thermo Scientific, MA5-12675) was used in immunoprecipitation on human samples and in western blot on human samples . Oncogene (2015) ncbi
mouse monoclonal (2F12)
  • proximity ligation assay; human; 1:40
In order to research p21 expression and HER2/HER3 heterodimers and prediction of adjuvant trastuzumab response in HER2+ breast cancer, Invitrogen Erbb3 antibody (Neomarkers, 2F12) was used in proximity ligation assay on human samples at 1:40. Breast Cancer Res Treat (2014) ncbi
mouse monoclonal (2F12)
  • western blot; human; fig 1c
In order to suggest that Akt activation by ERBB3/HER2 limits the effectiveness of EGFR inhibition, Invitrogen Erbb3 antibody (Thermo Scientific, 2F12) was used in western blot on human samples (fig 1c). Mol Cancer Ther (2014) ncbi
mouse monoclonal (2F12)
  • western blot; human; fig 5
In order to discuss targeting MiR-221/-222 to treat breast cancer, Invitrogen Erbb3 antibody (Thermo Scientific, MS-201-P1) was used in western blot on human samples (fig 5). Br J Cancer (2013) ncbi
mouse monoclonal (2B5)
  • immunoprecipitation; mouse; 1:1000
In order to study targeting sEcad for treatment of breast cancer, Invitrogen Erbb3 antibody (Thermo Fisher Scientific, Ab-6) was used in immunoprecipitation on mouse samples at 1:1000. Mol Carcinog (2014) ncbi
mouse monoclonal (2B5)
  • immunoprecipitation; human
  • western blot; human
In order to examine the role of E-cadherin and ADAM15 in ErbB receptor signaling, Invitrogen Erbb3 antibody (Lab Vision, 2B5) was used in immunoprecipitation on human samples and in western blot on human samples . J Biol Chem (2008) ncbi
mouse monoclonal (RTJ2)
  • immunocytochemistry; human; fig 6
In order to assess the morphogenetic activities of c-erbB and retinoids on human mammary epithelial cells, Invitrogen Erbb3 antibody (Neomarkers, RTJ.2) was used in immunocytochemistry on human samples (fig 6). J Cell Physiol (2003) ncbi
Santa Cruz Biotechnology
mouse monoclonal (G-4)
  • western blot; human; loading ...; fig 2b
In order to study the role of nuclear ErbB3 in normal and tumor prostate tissues, Santa Cruz Biotechnology Erbb3 antibody (Santa Cruz Biotechnology, sc-7390) was used in western blot on human samples (fig 2b). PLoS ONE (2016) ncbi
mouse monoclonal (G-4)
  • proximity ligation assay; human; 1:300; fig 2
  • western blot; human; fig 2
Santa Cruz Biotechnology Erbb3 antibody (Santa Cruz, G-4) was used in proximity ligation assay on human samples at 1:300 (fig 2) and in western blot on human samples (fig 2). Oncotarget (2016) ncbi
mouse monoclonal (SGP1)
  • flow cytometry; human; fig 1a
Santa Cruz Biotechnology Erbb3 antibody (Santa Cruz, SC53279) was used in flow cytometry on human samples (fig 1a). Oncotarget (2014) ncbi
mouse monoclonal (G-4)
  • western blot; human; fig 6
Santa Cruz Biotechnology Erbb3 antibody (Santa Cruz Biotechnology, sc-7390) was used in western blot on human samples (fig 6). Genes Dev (2013) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (21D3)
  • other; human; 1:100; loading ...; fig 2b
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791S) was used in other on human samples at 1:100 (fig 2b). elife (2020) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; 1:500; loading ...; fig 4b
Cell Signaling Technology Erbb3 antibody (Cell Signaling Technologies, 4791) was used in western blot on human samples at 1:500 (fig 4b). elife (2019) ncbi
domestic rabbit monoclonal (D1B5)
  • western blot; human; loading ...; fig 1d
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 2842) was used in western blot on human samples (fig 1d). Breast Cancer Res (2019) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; loading ...; fig 1c
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 1c). J Biol Chem (2019) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; loading ...; fig 1c
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4754) was used in western blot on human samples (fig 1c). J Biol Chem (2019) ncbi
domestic rabbit monoclonal (C56E4)
  • western blot; human; loading ...; fig s1b
Cell Signaling Technology Erbb3 antibody (Cell Signaling Technology, 4561) was used in western blot on human samples (fig s1b). Proc Natl Acad Sci U S A (2018) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; loading ...; fig 5e
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4754) was used in western blot on human samples (fig 5e). Cell Res (2018) ncbi
domestic rabbit monoclonal (21D3)
  • other; human; loading ...; fig 4c
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791) was used in other on human samples (fig 4c). Cancer Cell (2018) ncbi
domestic rabbit monoclonal (21D3)
  • reverse phase protein lysate microarray; human; loading ...; fig st6
In order to characterize the molecular identity of uterine carcinosarcomas., Cell Signaling Technology Erbb3 antibody (CST, 4791) was used in reverse phase protein lysate microarray on human samples (fig st6). Cancer Cell (2017) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; rat; 1:1000; loading ...; fig 5c
In order to explore the role of Necl4 in peripheral myelination, Cell Signaling Technology Erbb3 antibody (Cell Signaling Technologies, 4791) was used in western blot on rat samples at 1:1000 (fig 5c). J Biol Chem (2017) ncbi
domestic rabbit monoclonal (21D3)
  • reverse phase protein lysate microarray; human; loading ...; fig 3a
In order to describe the features of 228 primary cervical cancers, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791) was used in reverse phase protein lysate microarray on human samples (fig 3a). Nature (2017) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; 1:1000; loading ...; fig 3
In order to assess the contribution of amphiregulin, epidermal growth factor, heparin-binding epidermal growth factor, and transforming growth factor alpha in the responsiveness of gastric cancer cell lines to cetuximab and trastuzumab, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4754) was used in western blot on human samples at 1:1000 (fig 3). J Cancer Res Clin Oncol (2017) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; loading ...; fig 10a
In order to study chaperome complexes in a large set of tumor specimens, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4754) was used in western blot on human samples (fig 10a). Nature (2016) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; loading ...; fig 3a, 3b
In order to study the contribution of the heregulin-1/HER3-driven pathway to hepatocellular carcinoma, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4754) was used in western blot on human samples (fig 3a, 3b). J Exp Clin Cancer Res (2016) ncbi
domestic rabbit monoclonal (C56E4)
  • western blot; human; loading ...; fig 6a
In order to study the contribution of the heregulin-1/HER3-driven pathway to hepatocellular carcinoma, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4561) was used in western blot on human samples (fig 6a). J Exp Clin Cancer Res (2016) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; loading ...; fig 6a, 6d
In order to study the contribution of the heregulin-1/HER3-driven pathway to hepatocellular carcinoma, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 6a, 6d). J Exp Clin Cancer Res (2016) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; 1:1000; loading ...; fig 3
Cell Signaling Technology Erbb3 antibody (Cell Signaling Technology, 4791) was used in western blot on human samples at 1:1000 (fig 3). Oncotarget (2016) ncbi
domestic rabbit monoclonal (21D3)
  • immunohistochemistry - paraffin section; human; 1:50; fig 1g
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 21D3) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 1g). Oncol Lett (2016) ncbi
domestic rabbit monoclonal (21D3)
  • immunohistochemistry - paraffin section; mouse; fig 6
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791) was used in immunohistochemistry - paraffin section on mouse samples (fig 6). Oncotarget (2016) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; fig 1
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 1). Oncogenesis (2016) ncbi
domestic rabbit monoclonal (1B2E)
  • immunohistochemistry - paraffin section; human; 1:50; fig s1
In order to utilize ovarian cancer xenograft models to study dynamic modulation of phosphoprotein expression, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4754) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig s1). BMC Cancer (2016) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; fig 3e
In order to determine how hepatitis C virus activates a neuregulin-driven circuit to modify surface expression of growth factor receptors of the ErbB family, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 3e). PLoS ONE (2016) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; fig 1b
In order to determine how hepatitis C virus activates a neuregulin-driven circuit to modify surface expression of growth factor receptors of the ErbB family, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4754) was used in western blot on human samples (fig 1b). PLoS ONE (2016) ncbi
domestic rabbit monoclonal (D1B5)
  • western blot; human; 1:1000; fig 4b
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 2842) was used in western blot on human samples at 1:1000 (fig 4b). Oncotarget (2016) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; fig 1
Cell Signaling Technology Erbb3 antibody (Cell Signaling Technology, 4791) was used in western blot on human samples (fig 1). Tumour Biol (2016) ncbi
domestic rabbit monoclonal (D1B5)
  • western blot; human; loading ...; fig 3c
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 2842) was used in western blot on human samples (fig 3c). Oncogene (2016) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; loading ...; fig s3b
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4754) was used in western blot on human samples (fig s3b). Oncogene (2016) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; fig 1
In order to study how ZEB1 drives the epithelial-mesenchymal transition-related resistance to EGFR-tyrosine kinases inhibitors in non-small cell lung cancer, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 1). PLoS ONE (2016) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; fig 2
Cell Signaling Technology Erbb3 antibody (Cell Signalling, 4754S) was used in western blot on human samples (fig 2). Oxid Med Cell Longev (2016) ncbi
domestic rabbit monoclonal (21D3)
  • immunocytochemistry; human; fig s3
  • western blot; human; fig 1
In order to study the interactions between PMCA2 and HER2 in breast cancer cells, Cell Signaling Technology Erbb3 antibody (Cell Signaling Technology, 4791) was used in immunocytochemistry on human samples (fig s3) and in western blot on human samples (fig 1). Proc Natl Acad Sci U S A (2016) ncbi
domestic rabbit monoclonal (21D3)
  • immunohistochemistry - paraffin section; human; 1:100
In order to determine the mechanisms of resistance to the pan-HER family inhibitor AZD8931, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791) was used in immunohistochemistry - paraffin section on human samples at 1:100. Dis Model Mech (2016) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; loading ...; fig 1
In order to investigate the in vitro anti-tumor activity of afatinib., Cell Signaling Technology Erbb3 antibody (Cell Signaling Technology, 4791) was used in western blot on human samples (fig 1). Target Oncol (2016) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; loading ...; fig 3a
Cell Signaling Technology Erbb3 antibody (Cell signaling, 4791) was used in western blot on human samples (fig 3a). Oncotarget (2016) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; fig 2
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 21D3) was used in western blot on human samples (fig 2). Oncotarget (2016) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; loading ...; fig 2a
Cell Signaling Technology Erbb3 antibody (Cell signaling, 4754) was used in western blot on human samples (fig 2a). J Biol Chem (2015) ncbi
domestic rabbit monoclonal (C56E4)
  • western blot; human; loading ...; fig 2a
Cell Signaling Technology Erbb3 antibody (Cell signaling, 4561) was used in western blot on human samples (fig 2a). J Biol Chem (2015) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; 1:200; fig 1
In order to study anti-tumor activity of breast cancer models resistant to anti-HER2 drugs due to a dual fatty acid synthase and HER2 signaling blockade, Cell Signaling Technology Erbb3 antibody (Cell signaling, 4754) was used in western blot on human samples at 1:200 (fig 1). PLoS ONE (2015) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; 1:200; fig 1
In order to study anti-tumor activity of breast cancer models resistant to anti-HER2 drugs due to a dual fatty acid synthase and HER2 signaling blockade, Cell Signaling Technology Erbb3 antibody (Cell signaling, 4791) was used in western blot on human samples at 1:200 (fig 1). PLoS ONE (2015) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; fig 2
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 2). Oncotarget (2015) ncbi
domestic rabbit monoclonal (C56E4)
  • western blot; human; fig 2
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4561) was used in western blot on human samples (fig 2). Oncotarget (2015) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; fig s3
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4754) was used in western blot on human samples (fig s3). Oncotarget (2015) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human
In order to study the effect of using an ADAM17 inhibitory antibody, MEDI3622, in several EGFR-dependent tumor models, Cell Signaling Technology Erbb3 antibody (Cell Signaling Technology, 4791) was used in western blot on human samples . Mol Cancer Ther (2015) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; loading ...; fig 4f, 4h
Cell Signaling Technology Erbb3 antibody (Cell Signaling Technology, 4754) was used in western blot on human samples (fig 4f, 4h). Oncotarget (2015) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; 1:1000; fig 1a
In order to examine an immunoblot-analysis workflow for accuracy and precision, Cell Signaling Technology Erbb3 antibody (Cell Signaling TECHNOLOGY, 4754) was used in western blot on human samples at 1:1000 (fig 1a). Sci Signal (2015) ncbi
domestic rabbit monoclonal (21D3)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 5b
  • western blot; mouse; loading ...; fig 1c
Cell Signaling Technology Erbb3 antibody (Cell Signaling Technologies, 4791) was used in immunohistochemistry - paraffin section on mouse samples (fig 5b) and in western blot on mouse samples (fig 1c). Cancer Chemother Pharmacol (2015) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; fig 2
In order to study human breast cancer cell lines and how Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration, Cell Signaling Technology Erbb3 antibody (Cell signaling, 21D3) was used in western blot on human samples (fig 2). Oncotarget (2015) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; fig 3
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791S) was used in western blot on human samples (fig 3). Proteomics (2015) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; fig 3
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4754S) was used in western blot on human samples (fig 3). Proteomics (2015) ncbi
domestic rabbit monoclonal (21D3)
  • immunohistochemistry; human; 1:30
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 21D3) was used in immunohistochemistry on human samples at 1:30. Anticancer Res (2014) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human
Cell Signaling Technology Erbb3 antibody (Cell Signaling Technology, 4791) was used in western blot on human samples . Cancer Res (2014) ncbi
domestic rabbit monoclonal (C56E4)
  • western blot; human
Cell Signaling Technology Erbb3 antibody (Cell Signaling Technology, 4561) was used in western blot on human samples . Cancer Res (2014) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human
Cell Signaling Technology Erbb3 antibody (Cell Signaling Technology, 4754) was used in western blot on human samples . Cancer Res (2014) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human
In order to study mechanism of resistance to the FGFR inhibitor BGJ398 and the FGFR inhibitor ponatinib, Cell Signaling Technology Erbb3 antibody (cell signaling, 4791S) was used in western blot on human samples . Oncogene (2015) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; fig 1c
In order to suggest that Akt activation by ERBB3/HER2 limits the effectiveness of EGFR inhibition, Cell Signaling Technology Erbb3 antibody (Cell Signaling Technology, 4791) was used in western blot on human samples (fig 1c). Mol Cancer Ther (2014) ncbi
domestic rabbit monoclonal (1B2E)
  • western blot; human; fig 2
In order to study targeting sEcad for treatment of breast cancer, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4754) was used in western blot on human samples (fig 2). Mol Carcinog (2014) ncbi
domestic rabbit monoclonal (C56E4)
  • western blot; human; fig 2
In order to study targeting sEcad for treatment of breast cancer, Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4561) was used in western blot on human samples (fig 2). Mol Carcinog (2014) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human; fig 3
Cell Signaling Technology Erbb3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 3). Genes Dev (2013) ncbi
domestic rabbit monoclonal (21D3)
  • western blot; human
Cell Signaling Technology Erbb3 antibody (Cell Signaling Technology, 21D3) was used in western blot on human samples . Breast Cancer Res (2011) ncbi
Articles Reviewed
  1. Choi B, Cha M, Eun G, Lee D, Lee S, Ehsan M, et al. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers. elife. 2020;9: pubmed publisher
  2. Hegde G, de la Cruz C, Giltnane J, Crocker L, Venkatanarayan A, Schaefer G, et al. NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma. elife. 2019;8: pubmed publisher
  3. Kennedy S, Han J, Portman N, Nobis M, Hastings J, Murphy K, et al. Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. Breast Cancer Res. 2019;21:43 pubmed publisher
  4. Turowec J, Lau E, Wang X, Brown K, Fellouse F, Jawanda K, et al. Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response. J Biol Chem. 2019;294:1396-1409 pubmed publisher
  5. Fan P, Narzisi G, Jayaprakash A, Venturini E, Robine N, Smibert P, et al. YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci U S A. 2018;115:E6030-E6038 pubmed publisher
  6. Xue Z, Vis D, Bruna A, Sustic T, van Wageningen S, Batra A, et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 2018;28:719-729 pubmed publisher
  7. Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed publisher
  8. Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31:411-423 pubmed publisher
  9. Heffernan C, Jain M, Liu T, Kim H, Barretto K, Li H, et al. Nectin-like 4 Complexes with Choline Transporter-like Protein-1 and Regulates Schwann Cell Choline Homeostasis and Lipid Biogenesis in Vitro. J Biol Chem. 2017;292:4484-4498 pubmed publisher
  10. . Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378-384 pubmed publisher
  11. Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S, et al. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol. 2017;143:573-600 pubmed publisher
  12. Rodina A, Wang T, Yan P, Gomes E, Dunphy M, Pillarsetty N, et al. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016;538:397-401 pubmed publisher
  13. Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Meratbene F, et al. Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin. J Exp Clin Cancer Res. 2016;35:126 pubmed publisher
  14. Alver T, Lavelle T, Longva A, Øy G, Hovig E, Bøe S. MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma. Oncotarget. 2016;7:55128-55140 pubmed publisher
  15. Lattanzio R, Veschi S, Aceto G, Curia M, Cama A, De Lellis L, et al. Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants. Oncol Lett. 2016;12:453-458 pubmed
  16. El Maassarani M, Barbarin A, Fromont G, Kaissi O, Lebbe M, Vannier B, et al. Integrated and Functional Genomics Analysis Validates the Relevance of the Nuclear Variant ErbB380kDa in Prostate Cancer Progression. PLoS ONE. 2016;11:e0155950 pubmed publisher
  17. Mancini M, Lien E, Toker A. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. Oncotarget. 2016;7:17301-13 pubmed publisher
  18. Meng Y, Zheng L, Yang Y, Wang H, Dong J, Wang C, et al. A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors. Oncogenesis. 2016;5:e211 pubmed publisher
  19. Szymanska M, Fosdahl A, Raiborg C, Dietrich M, Liestøl K, Stang E, et al. Interaction with epsin 1 regulates the constitutive clathrin-dependent internalization of ErbB3. Biochim Biophys Acta. 2016;1863:1179-88 pubmed publisher
  20. Koussounadis A, Langdon S, Um I, Kay C, Francis K, Harrison D, et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016;16:205 pubmed publisher
  21. Stindt S, Cebula P, Albrecht U, Keitel V, Schulte Am Esch J, Knoefel W, et al. Hepatitis C Virus Activates a Neuregulin-Driven Circuit to Modify Surface Expression of Growth Factor Receptors of the ErbB Family. PLoS ONE. 2016;11:e0148711 pubmed publisher
  22. Ebbing E, Medema J, Damhofer H, Meijer S, Krishnadath K, van Berge Henegouwen M, et al. ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. Oncotarget. 2016;7:10243-54 pubmed publisher
  23. Cao K, Gong H, Qiu Z, Wen Q, Zhang B, Tang T, et al. Hepatitis B virus X protein reduces the stability of Nrdp1 to up-regulate ErbB3 in hepatocellular carcinoma cells. Tumour Biol. 2016;37:10375-82 pubmed publisher
  24. Teng Y, Pi W, Wang Y, Cowell J. WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling. Oncogene. 2016;35:4633-40 pubmed publisher
  25. Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam K, et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE. 2016;11:e0147344 pubmed publisher
  26. Khalil H, Langdon S, Kankia I, Bown J, Deeni Y. NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies. Oxid Med Cell Longev. 2016;2016:4148791 pubmed publisher
  27. Jeong J, VanHouten J, Dann P, Kim W, Sullivan C, Yu H, et al. PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer. Proc Natl Acad Sci U S A. 2016;113:E282-90 pubmed publisher
  28. Creedon H, Balderstone L, Muir M, Balla J, Gómez Cuadrado L, Tracey N, et al. Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer. Dis Model Mech. 2016;9:131-40 pubmed publisher
  29. Huguet F, Fernet M, Giocanti N, Favaudon V, Larsen A. Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. Target Oncol. 2016;11:371-81 pubmed publisher
  30. Chen J, Chen Y, Yen C, Chen W, Huang W. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget. 2016;7:473-89 pubmed publisher
  31. Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomić T, et al. HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget. 2016;7:433-45 pubmed publisher
  32. Capparelli C, Rosenbaum S, Berger A, Aplin A. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma. J Biol Chem. 2015;290:24267-77 pubmed publisher
  33. Blancafort A, Giró Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ã, et al. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. PLoS ONE. 2015;10:e0131241 pubmed publisher
  34. Hutchinson K, Johnson D, Johnson A, Sanchez V, Kuba M, Lu P, et al. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget. 2015;6:22348-60 pubmed
  35. Rios Doria J, Sabol D, Chesebrough J, Stewart D, Xu L, Tammali R, et al. A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways. Mol Cancer Ther. 2015;14:1637-49 pubmed publisher
  36. Ferreira R, Law M, Jahn S, Davis B, Heldermon C, Reinhard M, et al. Novel agents that downregulate EGFR, HER2, and HER3 in parallel. Oncotarget. 2015;6:10445-59 pubmed
  37. Janes K. An analysis of critical factors for quantitative immunoblotting. Sci Signal. 2015;8:rs2 pubmed publisher
  38. Meneses Lorente G, Friess T, Kolm I, Hölzlwimmer G, Bader S, Meille C, et al. Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody. Cancer Chemother Pharmacol. 2015;75:837-50 pubmed publisher
  39. Momeny M, Saunus J, Marturana F, McCart Reed A, Black D, Sala G, et al. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget. 2015;6:3932-46 pubmed
  40. Blair B, Wu X, Zahari M, Mohseni M, Cidado J, Wong H, et al. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics. 2015;15:318-26 pubmed publisher
  41. Falkenberg N, Anastasov N, Höfig I, Bashkueva K, Lindner K, Höfler H, et al. Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo. Mol Oncol. 2015;9:282-94 pubmed publisher
  42. Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, et al. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget. 2014;5:7138-48 pubmed
  43. Cha Y, Han S, Seol H, Oh D, Im S, Bang Y, et al. Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Res. 2014;34:4275-80 pubmed
  44. Kugel C, Hartsough E, Davies M, Setiady Y, Aplin A. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res. 2014;74:4122-32 pubmed publisher
  45. Wang J, Mikse O, Liao R, Li Y, Tan L, Jänne P, et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015;34:2167-77 pubmed publisher
  46. Green A, Barros F, Abdel Fatah T, Moseley P, Nolan C, Durham A, et al. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast Cancer Res Treat. 2014;145:33-44 pubmed publisher
  47. Zhang L, Castanaro C, Luan B, Yang K, Fan L, Fairhurst J, et al. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol Cancer Ther. 2014;13:1345-55 pubmed publisher
  48. Falkenberg N, Anastasov N, Rappl K, Braselmann H, Auer G, Walch A, et al. MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. Br J Cancer. 2013;109:2714-23 pubmed publisher
  49. Brouxhon S, Kyrkanides S, Teng X, O Banion M, Clarke R, Byers S, et al. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers. Mol Carcinog. 2014;53:893-906 pubmed publisher
  50. Ni M, Chen Y, Fei T, Li D, Lim E, Liu X, et al. Amplitude modulation of androgen signaling by c-MYC. Genes Dev. 2013;27:734-48 pubmed publisher
  51. Lindberg K, Helguero L, Omoto Y, Gustafsson J, Haldosén L. Estrogen receptor ? represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res. 2011;13:R43 pubmed publisher
  52. Najy A, Day K, Day M. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem. 2008;283:18393-401 pubmed publisher
  53. Offterdinger M, Schneider S, Grunt T. Heregulin and retinoids synergistically induce branching morphogenesis of breast cancer cells cultivated in 3D collagen gels. J Cell Physiol. 2003;195:260-75 pubmed